Surf Bio, Inc.

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

The series C venture capital round that Tessera Therapeutics announced on 19 April – totaling more than $300m, the company said – shows that investors continue to be willing to invest large sums in